Albumin
(Human) 25%, USP
Category:
Description:
Indications:
-
Emergency
treatment of hypovolemic shock, burn therapy, cardiopulmonary bypass
-
Hypoproteinemia
with or without edema, adult respiratory distress syndrome (ARDS)
-
Acute
liver failure, neonatal hemolytic disease
-
Erythrocyte
resuspension, sequestration of protein rich foods
-
Acute
neophrosis
Contraindications:
Precautions:
-
Pregnancy
category C
-
Monitor
against signs of circulatory overload. Albumin 25% is hyperoncotic,
therefore, in the presence of dehydration, albumin must be followed by
addition of fluids.
-
In
presence of hemorrhage, albumin should be supplemented by the
transfusion of whole blood to treat the relative anemia associated
with hemodilution. When circulating blood volume has been reduced,
hemodilution following the administration of albumin persists for many
hours. In patients with
normal blood volume, hemodilution lasts for a much shorter time.
-
The
rapid rise in blood pressure may follow the administration of a
colloid with positive oncotic activity necessitates careful
observation to detect and treat severed blood vessels which may not
have bled at the lower blood pressure.
Adverse
Reactions (Side Effects):
-
Rare:
Such reactions may be allergic in nature or due to high plasma protein
levels from excessive albumin administration. Allergic manifestations include urticaria, chills, fever, and
changes in pulse, respiration and blood pressure.
|
Dosage:
Always
administered by intravenous infusion; albumin 25% may be administered
undiluted or diluted in 0.9% Sodium Chloride or 5% Dextrose in Water.
-
Hypovolemic
shock:
The volume administered and the speed of infusion should be adapted to the response of the patient
-
Burns:
After a burn injury (usually 24 hours) there is a close correlation
between the amount of albumin infused and the resultant increase in
plasma colloid osmotic pressure. The aim should be to maintain the plasma albumin concentration
in the region of 2.5 , plus or minus 0.5g, per 100ml with a plasma
oncotic pressure of 22 mm Hg. This is best achieved by IV administration of albumin 25%. The duration of therapy is decided by the loss of protein from
the burned areas and in the urine, In addition, oral or parenteral feeding with amino acids should
be initiated, as the long-term administration of albumin should not be
considered as a source of nutrition.
-
Hypoproteinemia
with or without edema:
Unless the underlying pathology for hypoproteinemia can be corrected,
the IV administration of albumin 25% must be considered purely
symptomatic or supportive. The
usual daily dose of albumin for adults is 50 to 75g and for children
25g. Patients with severe
hypoproteinemia who continue to lose albumin may require larger
quantities. Since
hypoproteinemic patients usually have normal blood volumes, the rate
of administration should not exceed 2 ml/min as more rapid injection
may precipitate circulatory embarrassment and pulmonary edema.
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|